Page last updated: 2024-08-21

treosulfan and Lymphoma

treosulfan has been researched along with Lymphoma in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boysen, G; Danylesko, I; Nagler, A; Shimoni, A; Varda-Bloom, N1
Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Abedi-Valugerdi, M; Hassan, M; Pillai, PR; Sadeghi, B; Wolfsberger, J; Zhao, Y; Zheng, W1
Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A1
Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M1
Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM1

Trials

3 trial(s) available for treosulfan and Lymphoma

ArticleYear
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Bone marrow transplantation, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine

2015
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
    Annals of hematology, 2004, Volume: 83 Suppl 1

    Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
    Bone marrow transplantation, 2004, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous

2004

Other Studies

3 other study(ies) available for treosulfan and Lymphoma

ArticleYear
A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan.
    Rapid communications in mass spectrometry : RCM, 2019, Nov-15, Volume: 33, Issue:21

    Topics: Adult; Aged; Busulfan; Chromatography, Liquid; Female; Hemoglobins; Humans; Leukemia; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Tandem Mass Spectrometry; Transplantation Conditioning; Transplantation, Homologous; Valine; Young Adult

2019
Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice.
    International immunopharmacology, 2016, Volume: 40

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Busulfan; Cell Line, Tumor; Drug Interactions; Female; Fluorouracil; Immunosuppressive Agents; Leukocyte Count; Lymphoma; Mice, Inbred C57BL; Myeloid Cells; Spleen; Tumor Burden

2016
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
    Annals of internal medicine, 1985, Volume: 103, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Leukemia; Lymphoma; Male; Mechlorethamine; Middle Aged; Myeloproliferative Disorders; Nitrosourea Compounds; Ovarian Neoplasms; Preleukemia; Risk; Time Factors

1985